BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29778570)

  • 1. Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity.
    Tian H; He Y; Song X; Jiang L; Luo J; Xu Y; Zhang W; Gao X; Yao W
    Cancer Lett; 2018 Aug; 430():79-87. PubMed ID: 29778570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Acquisition of Fully Human Antibody Genes against Self-Proteins by Sorting Single B Cells Stimulated with Vaccines Based on Nitrated T Helper Cell Epitopes.
    Jiang L; Jiang T; Luo J; Kang Y; Tong Y; Song X; Gao X; Yao W; Tian H
    J Immunol Res; 2019; 2019():7914326. PubMed ID: 32083142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
    Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
    Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine.
    Wang L; Miyahara Y; Kato T; Wang L; Aota T; Kuribayashi K; Shiku H
    Cancer Immun; 2003 Nov; 3():16. PubMed ID: 14629132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice.
    Renard V; Sonderbye L; Ebbehøj K; Rasmussen PB; Gregorius K; Gottschalk T; Mouritsen S; Gautam A; Leach DR
    J Immunol; 2003 Aug; 171(3):1588-95. PubMed ID: 12874253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles.
    Pouyanfard S; Bamdad T; Hashemi H; Bandehpour M; Kazemi B
    PLoS One; 2012; 7(11):e49539. PubMed ID: 23166703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with HER2 extracellular subdomain proteins induces cellular response and tumor growth inhibition in mice.
    Ahmadi M; Sadri-Ardalani F; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
    Immunotherapy; 2018 Mar; 10(6):511-524. PubMed ID: 29562854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
    Rice J; Buchan S; Stevenson FK
    J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
    Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
    J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
    Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
    J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine-Induced Memory CD8
    Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
    Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.